Erik Lavington's questions to Kura Oncology Inc (KURA) leadership • Q2 2025
Question
Erik Lavington, on for Salveen Richter, asked for Kura's thoughts on the potential launch ramp for Zifdomenib in relapsed/refractory NPM1-mutant AML and whether a 'warehousing' of patients might occur, unlike what was seen for KMT2A-rearranged AML.
Answer
Chief Commercial Officer Brian Powl explained that the company is not providing specific launch ramp guidance but does not expect a large bolus or 'warehousing' of patients. He reasoned that this is an elderly, heavily pretreated population with a high unmet need and short life expectancy, making it unlikely for patients to wait for a new therapy.